Business Wire

Percona Redefines Cloud-Native Database Management with Percona Everest: the World's First Open Source Public DBaaS Alternative

Share

Percona, a global leader in enterprise-grade open source database software and services, today announced that its groundbreaking new database platform, Percona Everest, is now generally available to the public. Percona Everest is an open source, cloud-native database platform designed to deliver similar core capabilities and conveniences provided by database-as-a-service (DBaaS) offerings but without the burden of vendor lock-in and associated challenges.

Percona Everest facilitates the work of developers, QA engineers, DevOps engineers, database administrators, and anyone who could benefit from self-serve deployment and management of MySQL, PostgreSQL and MongoDB on Kubernetes. Percona Everest simplifies database management and enables database deployment standardization across multiple clouds and environments. Percona Everest helps enterprises accelerate business operations through its reliable, scalable, and secure cloud-native database infrastructure architecture.

“Percona Everest represents a paradigm shift in the management of cloud-native databases on Kubernetes,” said Ann Schlemmer, CEO at Percona. “After several years of significant growth in the public DBaaS market, organizations are pushing back against public DBaaS solutions that actively cultivate lock-in, limiting flexibility and driving up costs for customers. We developed Percona Everest to counter these issues, providing our customers with the conveniences of the leading public DBaaS offerings but without the limitations.”

As organizations look to build more products and services in the cloud, many are beginning to discover a host of hidden costs associated with popular public DBaaS offerings. Even when compared to other types of proprietary, “as-a-service” solutions, public DBaaS offerings can be particularly effective in cultivating vendor lock-in, making it exceedingly difficult for customers to maintain control over data access, database configurations, and cloud costs.

Percona Everest was designed with these very issues in mind. Unlike traditional DBaaS offerings, Percona Everest does not function as hosted infrastructure. Instead, Percona Everest allows organizations to self-serve provision and manage highly performant, open source database clusters on Kubernetes using the infrastructure they control—whether it be a cloud of their choosing, on-premises, or both. As a result, users of Percona Everest maintain control over mission-critical matters, including data access, database configuration, and costs associated with running databases in the cloud. Percona Everest extends the benefits of platform engineering to database provisioning and management.

Multi-Database, Multi-Cluster, Comprehensive Capabilities Combined with Expert Support

Percona Everest brings together the automated provisioning and management of multiple databases across different environments, all within a single, intuitive, multi-cloud user interface. By leveraging automation, users can create enterprise-ready database instances of MySQL, MongoDB, and PostgreSQL in minutes. Percona Everest enables the creation of databases pre-configured with optimal parameters and settings for available resources. Key features include:

  • Multi-Database Support: Manage various database technologies, including MySQL, MongoDB, and PostgreSQL, within a unified platform.
  • Kubernetes-Based Deployments: Run both development environments and databases on Kubernetes to automate database management and provisioning, simplifying and accelerating application development.
  • Multi-Cloud and On-Premise Deployments: Deploy databases across multiple clouds or on-premises infrastructure, including OpenShift, to ensure redundancy, high availability, and data sovereignty.
  • Private and Custom Deployments: Maintain the privacy and security of the database environment with private deployments, enabling customization of every aspect of the database setup.
  • Intuitive User Interface: Simplify administrative tasks with the ability to add and manage storage locations, monitoring endpoints, storage classes, and other default configurations from a central interface.
  • Comprehensive Monitoring: Gain insights into performance metrics, query analysis, and more with the integrated Percona Monitoring and Management (PMM) tool.
  • Single Sign-On (SSO) Integration: Centralize user authentication, simplify access, and enhance security across your database deployments.
  • Disaster Recovery: Maintain business continuity with tools that support high availability and disaster recovery.

Percona offers enterprise-grade support for Percona Everest users and all their database deployments. In keeping with Percona’s spirit of flexibility and choice, Percona Everest users can opt to manage their cloud-native database platform independently or with the help and support of Percona's team of database performance experts. The Percona team is always available to support any organization making the transition to Kubernetes-based deployments.

Early Adopters Benefit From, Build With Percona Everest

Percona introduced Everest to a select group of customers earlier this year. Adoption has been growing steadily, and users are extolling the platform’s benefits.

“In designing our DBaaS service for customers, we knew that companies would want the benefits of technologies like Kubernetes and cloud-native services while avoiding the costly and extremely challenging aspects of running this themselves,” said Handoyo Sutanto, CEO and Co-Founder of Lyrid. “With Percona Everest, we have built a fully managed, flexible database service for our customers which we can provide without the levels of lock-in and expense associated with other cloud providers.”

Gifford Holmquist from Samaritan's Purse stated, "We migrated to Percona Everest from the Public Cloud in order to control our own data, reduce costs, and avoid vendor lock-in wherever possible. We’ve met each of these objectives, and we’re very happy with the move. It's been a very successful decision.”

Learn more about Percona Everest by visiting the Documentation section of the Percona website.

About Percona
Percona is a world-class open source database software, support, and services company. The organization is dedicated to helping businesses ensure their databases — and the applications that depend on them — are secure, compliant, performant, and highly available. Through a unique combination of database expertise and enterprise-grade open source software, Percona empowers organizations with the freedom to choose, the freedom to create, and the freedom to innovate with speed as they grow. For more information, visit www.percona.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240917948450/en/

Contacts

Media Contact:
Jacob Manchester
Scratch Marketing + Media for Percona
jacob@scratchmm.com
401-636-7757

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release

Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi

Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release

Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin

Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 15:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #

SLB Announces First-Quarter 2025 Results; Remains Committed to Return a Minimum of $4 Billion to Shareholders in 202525.4.2025 13:50:00 EEST | Press release

SLB (NYSE: SLB) today announced results for the first-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423635499/en/ The exterior of the SLB headquarters in Houston, Texas. First-Quarter Results (Stated in millions, except per share amounts) Three Months EndedChange Mar. 31, 2025 Dec. 31, 2024 Mar. 31, 2024 Sequential Year-on-year Revenue $8,490 $9,284 $8,707 -9% -3% Income before taxes - GAAP basis $1,063 $1,387 $1,357 -23% -22% Income before taxes margin - GAAP basis 12.5% 14.9% 15.6% -241 bps -306 bps Net income attributable to SLB - GAAP basis $797 $1,095 $1,068 -27% -25% Diluted EPS - GAAP basis $0.58 $0.77 $0.74 -25% -22% Adjusted EBITDA* $2,020 $2,382 $2,057 -15% -2% Adjusted EBITDA margin* 23.8% 25.7% 23.6% -186 bps 18 bps Pretax segment operating income* $1,556 $1,918 $1,649 -19% -6% Pretax segment operating margin* 18.3% 20.7% 18.9% -232 bps -60 bps Net income attributable to SLB, excluding charges &

Corona, The World’s Most Valuable Beer Brand 1 , Announces Its 100-Year Anniversary with Global Celebration25.4.2025 11:00:00 EEST | Press release

Today, Corona proudly celebrates its 100-year anniversary, a remarkable milestone for the iconic brand that has been synonymous with the beach and enjoyed by consumers worldwide for the past century. Since 1925, Corona has cultivated a deep association with the beach; fully embodying a lifestyle connected to nature and relaxation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425804516/en/ Corona 100 This Is Living Since 1925 In honor of the occasion, Corona invites everyone to live their “beach side” – a.k.a. their best side – at top-tier beach locations across the globe. The Corona 100 platform includes a film highlighting 100 years of beach culture, a definitive list of the top 100 beaches in the world to visit, and a signed multi-year sponsorship of a renowned concert at Copacabana Beach in Rio de Janeiro — all offering people across the globe opportunities to connect with their beach side. “For 100 years, Corona has

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye